Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Erben

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Haematologica|March 28, 2008
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinibPaul La Rosée, Susanne Holm-Eriksen, Heiko Konig, et al.
Journal of Clinical Medicine|April 8, 2020
FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical CystectomyDanijel Sikic, Markus Eckstein, Ralph M Wirtz, et al.
Blood|December 23, 2006
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisJorge Cortes, Philippe Rousselot, Dong-Wook Kim, et al.
Cancers|June 2, 2021
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer PatientsVeronika Weyerer, Pamela L Strissel, Reiner Strick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseTimothy Hughes, Giuseppe Saglio, Susan Branford, et al.
European Urology|April 8, 2023
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic EvolutionAlexander Cox, Niklas Klümper, Johannes Stein, et al.
Oncotarget|March 31, 2018
A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomyMarkus Eckstein, Ralph M Wirtz, Carolin Pfannstil, et al.
Annals of Hematology|November 28, 2013
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosisPhilipp Erben, Juliana Schwaab, Georgia Metzgeroth, et al.
Oncoimmunology|October 23, 2023
<i>PD-L1</i> (<i>CD274</i>) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinomaNiklas Klümper, Lennert Wüst, Jonas Saal, et al.
Cancers|December 28, 2019
miR-10a-5p and miR-29b-3p as Extracellular Vesicle-Associated Prostate Cancer Detection MarkersThomas Stefan Worst, Christopher Previti, Katja Nitschke, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Haematologica|March 28, 2008
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinibPaul La Rosée, Susanne Holm-Eriksen, Heiko Konig, et al.
Journal of Clinical Medicine|April 8, 2020
FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical CystectomyDanijel Sikic, Markus Eckstein, Ralph M Wirtz, et al.
Blood|December 23, 2006
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisJorge Cortes, Philippe Rousselot, Dong-Wook Kim, et al.
Cancers|June 2, 2021
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer PatientsVeronika Weyerer, Pamela L Strissel, Reiner Strick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseTimothy Hughes, Giuseppe Saglio, Susan Branford, et al.
European Urology|April 8, 2023
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic EvolutionAlexander Cox, Niklas Klümper, Johannes Stein, et al.
Oncotarget|March 31, 2018
A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomyMarkus Eckstein, Ralph M Wirtz, Carolin Pfannstil, et al.
Annals of Hematology|November 28, 2013
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosisPhilipp Erben, Juliana Schwaab, Georgia Metzgeroth, et al.
Oncoimmunology|October 23, 2023
<i>PD-L1</i> (<i>CD274</i>) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinomaNiklas Klümper, Lennert Wüst, Jonas Saal, et al.
Cancers|December 28, 2019
miR-10a-5p and miR-29b-3p as Extracellular Vesicle-Associated Prostate Cancer Detection MarkersThomas Stefan Worst, Christopher Previti, Katja Nitschke, et al.
Pageof 13